MedTrace Logo

Body Weight, Aspirin Dose and Pro-resolving Mediators

NCT04697719 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 103

Last updated 2026-03-09

No results posted yet for this study

Summary

This study employs a placebo-controlled randomized cross-over design to investigate the impact of body weight and aspirin dose on levels of specialized pro-resolving lipid mediators in blood and neutrophils.

Conditions

  • Body Weight

Interventions

DRUG

Aspirin 81mg

81mg oral capsule

DRUG

Aspirin 325mg

325mg oral capsule

Sponsors & Collaborators

Principal Investigators

  • Sean Heffron, MD · NYU Langone Health

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-11-04
Primary Completion
2025-01-29
Completion
2025-01-29
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04697719 on ClinicalTrials.gov